Needham Upgrades Neurocrine Biosciences to Buy, Announces $138 Price Target

Benzinga · 04/15 11:36
Needham analyst Ami Fadia upgrades Neurocrine Biosciences (NASDAQ:NBIX) from Hold to Buy and announces $138 price target.